RecruitingPhase 1 / Phase 2NCT06973564
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
Rochester, MN · St Louis, MO · Cleveland, OH · +1 more sites
Phase 1/2 Colorectal Cancer clinical trials
57 recruiting Phase 1/2 colorectal cancer studies in the US. What trial phases mean
Other phases
RecruitingPhase 1 / Phase 2NCT06307548
Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer
Sponsor: Roswell Park Cancer Institute
Buffalo, NY
RecruitingPhase 1 / Phase 2NCT07020221
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Sponsor: Verastem, Inc.
Los Angeles, CA · Baltimore, MD · Boston, MA · +10 more sites
RecruitingPhase 1 / Phase 2NCT05786924
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Sponsor: Institut de Recherches Internationales Servier
Gilbert, AZ · Los Angeles, CA · +18 more sites
RecruitingPhase 1 / Phase 2NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Sponsor: Parabilis Medicines, Inc.
Phoenix, AZ · Scottsdale, AZ · Tucson, AZ · +28 more sites
RecruitingPhase 1 / Phase 2NCT06710756
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Sponsor: Perspective Therapeutics
Los Angeles, CA · Miami, FL · +13 more sites
RecruitingPhase 1 / Phase 2NCT06428409
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Sponsor: Merck Sharp & Dohme LLC
Los Angeles, CA · Aurora, CO · +10 more sites
RecruitingPhase 1 / Phase 2NCT07411599
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT07189871
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Sponsor: Radiopharm Theranostics, Ltd
Dothan, AL · Grand Rapids, MI · Omaha, NE · +2 more sites
RecruitingPhase 1 / Phase 2NCT05482893
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Sponsor: Phanes Therapeutics
Duarte, CA · Los Angeles, CA · Denver, CO · +8 more sites
RecruitingPhase 1 / Phase 2NCT06047379
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Sponsor: Neonc Technologies, Inc.
Beverly Hills, CA · Glendale, CA · Los Angeles, CA · +5 more sites
RecruitingPhase 1 / Phase 2NCT06445062
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Sponsor: Revolution Medicines, Inc.
Chandler, AZ · Phoenix, AZ · Scottsdale, AZ · +29 more sites
RecruitingPhase 1 / Phase 2NCT07262619
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Sponsor: Eikon Therapeutics
Los Angeles, CA · Doral, FL · Hialeah, FL · +7 more sites
RecruitingPhase 1 / Phase 2NCT07488676
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Sponsor: Astellas Pharma Global Development, Inc.
Birmingham, AL · Los Angeles, CA · Miami, FL · +15 more sites
RecruitingPhase 1 / Phase 2NCT06349590
Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery
Sponsor: University of Chicago
Chicago, IL
RecruitingPhase 1 / Phase 2NCT07629960
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Sponsor: Blueprint Medicines Corporation
Sarasota, FL · Tampa, FL · Baton Rouge, LA · +7 more sites
RecruitingPhase 1 / Phase 2NCT07693751
A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
Sponsor: SOTIO Biotech a.s.
Houston, TX · Faifax, VA
RecruitingPhase 1 / Phase 2NCT07213609
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Sponsor: GlaxoSmithKline
Aurora, CO · Detroit, MI · Canton, OH · +1 more sites
RecruitingPhase 1 / Phase 2NCT06638502
Safety of HRX215 in Patients After Minor and Major Liver Resection
Sponsor: HepaRegeniX GmbH
Baltimore, MD · Rochester, MN · Durham, NC · +1 more sites
RecruitingPhase 1 / Phase 2NCT07147231
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
Sponsor: National Cancer Institute (NCI)
Aurora, CO · Washington D.C., DC · Atlanta, GA · +4 more sites
RecruitingPhase 1 / Phase 2NCT04851119
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Sponsor: Children's Oncology Group
Birmingham, AL · Los Angeles, CA · Orange, CA · +18 more sites
RecruitingPhase 1 / Phase 2NCT03190941
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Sponsor: National Cancer Institute (NCI)
Bethesda, MD
RecruitingPhase 1 / Phase 2NCT03965234
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Sponsor: Roswell Park Cancer Institute
Buffalo, NY
RecruitingPhase 1 / Phase 2NCT07636785
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Sponsor: VM Discovery, Inc.
Scottsdale, AZ
RecruitingPhase 1 / Phase 2NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Clovis, CA · Los Angeles, CA · Newport Beach, CA · +8 more sites
RecruitingPhase 1 / Phase 2NCT07277322
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Sponsor: Dan Feng
New York, NY
RecruitingPhase 1 / Phase 2NCT05592626
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Sponsor: Marengo Therapeutics, Inc.
Sacramento, CA · Celebration, FL · Miami, FL · +10 more sites
RecruitingPhase 1 / Phase 2NCT06751329
A Study of DM002 in Patients With Advanced Solid Tumors
Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
San Francisco, CA · Huntersville, NC · Oklahoma City, OK · +1 more sites
RecruitingPhase 1 / Phase 2NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Sponsor: Daiichi Sankyo
Los Angeles, CA · Whittier, CA · +15 more sites
RecruitingPhase 1 / Phase 2NCT05691491
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Sponsor: National Cancer Institute (NCI)
Irvine, CA · La Jolla, CA · Orange, CA · +20 more sites
RecruitingPhase 1 / Phase 2NCT04657068
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Sponsor: Artios Pharma Ltd
Birmingham, AL · Scottsdale, AZ · Little Rock, AR · +38 more sites
RecruitingPhase 1 / Phase 2NCT03526835
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Sponsor: Merus B.V.
La Jolla, CA · Los Angeles, CA · San Diego, CA · +28 more sites
RecruitingPhase 1 / Phase 2NCT07169734
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Sponsor: Alentis Therapeutics AG
Phoenix, AZ · Los Angeles, CA · New Haven, CT · +6 more sites
RecruitingPhase 1 / Phase 2NCT07079631
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Sponsor: BioNTech SE
New Haven, CT · Grand Rapids, MI · Cleveland, OH · +1 more sites
RecruitingPhase 1 / Phase 2NCT06412198
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Sponsor: M.D. Anderson Cancer Center
Boston, MA · Houston, TX
RecruitingPhase 1 / Phase 2NCT07432633
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Sponsor: Blue Earth Diagnostics
Dallas, TX
RecruitingPhase 1 / Phase 2NCT06051695
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Sponsor: A2 Biotherapeutics Inc.
Gilbert, AZ · La Jolla, CA · Los Angeles, CA · +9 more sites
RecruitingPhase 1 / Phase 2NCT03947385
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Sponsor: IDEAYA Biosciences
Los Angeles, CA · San Francisco, CA · Denver, CO · +9 more sites
RecruitingPhase 1 / Phase 2NCT05552755
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
Sponsor: Recursion Pharmaceuticals Inc.
Scottsdale, AZ · Tucson, AZ · San Diego, CA · +14 more sites
RecruitingPhase 1 / Phase 2NCT06598007
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Sponsor: Crossignal Therapeutics, Inc.
Houston, TX
RecruitingPhase 1 / Phase 2NCT04421820
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Sponsor: Bold Therapeutics, Inc.
Santa Monica, CA · Tampa, FL
RecruitingPhase 1 / Phase 2NCT05379985
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Sponsor: Revolution Medicines, Inc.
Orange, CA · Santa Monica, CA · Tampa, FL · +18 more sites
RecruitingPhase 1 / Phase 2NCT05692024
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
Sponsor: Massachusetts General Hospital
Boston, MA
RecruitingPhase 1 / Phase 2NCT06362369
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Sponsor: 7 Hills Pharma, LLC
Aurora, CO · Lake Mary, FL · Lebanon, NH · +2 more sites
RecruitingPhase 1 / Phase 2NCT06395519
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Sponsor: 858 Therapeutics, Inc.
Phoenix, AZ · New Haven, CT · Jacksonville, FL · +11 more sites
RecruitingPhase 1 / Phase 2NCT06244771
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Sponsor: Frontier Medicines Corporation
La Jolla, CA · Orange, CA · San Francisco, CA · +12 more sites
RecruitingPhase 1 / Phase 2NCT07281716
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Sponsor: Dan Feng
New York, NY
RecruitingPhase 1 / Phase 2NCT07030257
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Sponsor: Tasca Therapeutics
Denver, CO · Orlando, FL · Grand Rapids, MI · +10 more sites
RecruitingPhase 1 / Phase 2NCT06055439
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Sponsor: Chimeric Therapeutics
Atlanta, GA · Chicago, IL · Philadelphia, PA · +1 more sites
RecruitingPhase 1 / Phase 2NCT07148128
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Sponsor: Auricula Biosciences Inc.
Dallas, TX · San Antonio, TX
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.